New pill targets Hard-to-Treat cancers in early human trial
NCT ID NCT07561554
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental oral drug called HSK42360-Na in 159 adults with advanced solid tumors that have a specific genetic change (BRAF V600 mutation). The main goals are to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug is shrinking tumors or slowing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSK42360-Na (oral drug)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific BRAF V600 mutation.
What could go wrong
This is an early Phase 1 trial with only 159 participants, so it is too soon to know if the drug works or is safe. Side effects are unknown, and the drug may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS (PHASE 1) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing TianTan Hospital,Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••